Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide Dose Titration in SHPT
NCT01414114Phase 2Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Dec 2011
- Primary completion
- May 2012
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by KAI Pharmaceuticals. Started Dec 2011; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01414114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414114.